[HTML][HTML] Direct-acting antivirals sofosbuvir and daclatasvir attenuate carbon tetrachloride-induced liver fibrosis in mice

MM Abdelsalam, N El-Mahdy, S Abou-Saif - Liver Research, 2023 - Elsevier
Background and aim Advanced liver fibrosis is a major risk for develo** hepatocellular
carcinoma (HCC) in chronic hepatitis C virus (HCV) patients. Direct-acting antivirals (DAAs) …

Discovery of terpenes as novel HCV NS5B polymerase inhibitors via molecular docking

TM Karpiński, M Ożarowski, PJ Silva, M Stasiewicz… - Pathogens, 2023 - mdpi.com
Hepatitis C virus (HCV) is a dangerous virus that is responsible for a large number of
infections and deaths worldwide. In the treatment of HCV, it is important that the drugs are …

Clinical Insights into Brucella Peritonitis: A Comprehensive Analysis of Four Cases

S Pan, Z Moming, A Awuti, K Zhou, M Tuerxun… - Journal of Epidemiology …, 2024 - Springer
Introduction Brucellosis, a globally distributed zoonotic disease, exhibits diverse clinical
manifestations, with Brucella peritonitis being a rare but consequential complication …

Treatment response and adverse effects of direct acting antivirals among HCV patients carrying comorbid conditions

DE Nishwa, HA Riaz, MS Tiwana, A Fatima… - Future …, 2024 - Taylor & Francis
Aim: Our study aimed to assess the response to direct-acting antiviral drugs (DAAs) among
hepatitis C virus (HCV)-infected patients who also had other comorbid conditions. Materials …

[HTML][HTML] Риск развития лекарственно-индуцированного поражения печени у пациентов с туберкулезом легких и хроническими вирусными гепатитами …

АВ Кукурика, ИА Васильева - Инфекционные болезни: Новости …, 2024 - cyberleninka.ru
Поражение печени, вызванное противотуберкулезными препаратами, представляет
серьезную проблему безопасности лечения туберкулеза. Влияние хронических …

[HTML][HTML] Risk of drug-induced liver injury in patients with pulmonary tuberculosis and chronic viral hepatitis: systematic review and meta-analysis

AV Kukurika, IA Vasilyeva - infect-dis-journal.ru
Risk of drug-induced liver injury in patients with pulmonary tuberculosis and chronic viral
hepatitis: systematic review and meta-analysis ISSN 2305-3496 (Print) ISSN 2658-7394 (Online) …

[PDF][PDF] BioScientific Review (BSR)

K Saleem, A Ali, S Rafique, N Rani, B Wahid, K Saleem… - academia.edu
Hepatitis-C virus (HCV) is an enveloped RNA virus that currently infects more than 180
million people, worldwide. Interferon therapy was previously used as a standard therapy for …

Epidemiology of tuberculosis and hepatitis C virus (HCV) co-infection in the country of Georgia

D Baliashvili - 2021 - search.proquest.com
Background: Tuberculosis and hepatitis C are major global public health problems. In
addition to the burden that these two diseases pose separately, a substantial proportion of …

Successful retreatment of HCV relapse patient with 4 weeks long sofsobuvir, ribavirin, and daclatasvir combination: Case Series

K Saleem, A Ali, S Rafique, N Rani… - BioScientific …, 2020 - journals.umt.edu.pk
Hepatitis-C virus (HCV) is an enveloped RNA virus that currently infects more than 180
million people, worldwide. Interferon therapy was previously used as a standard therapy for …

[PDF][PDF] Вирусный гепатит С у пациентов с туберкулезом органов дыхания

ЮГ Юпатов, ТИ Дмитраченко, ИВ Кучко - КЛИНИЧЕСКАЯ …, 2022 - recipe.by
Исследование включало 43 пациентов с коинфекцией ТБ/ГС и 48 пациентов с ТБ.
Результаты исследования не выявили повышенного риска гепатотоксичности …